1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
SenzaGen achieves 13% revenue growth in second quarter thanks to recovery at VitroScreen
SenzaGen reports a 13% increase in revenue in the second quarter to SEK 15.3 million, driven by a recovery at subsidiary VitroScreen and two large orders. The operating loss narrowed, earnings per share improved compared with the previous year, and operating cash flow was positive. The company maintained a stable gross margin, cited effective cost management, and expects EU regulations reducing animal testing to support long-term demand for its test solutions. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 1.38m | 13.78% |
| Gross profit | 914.91k | 18.09% |
| Net profit | -200.15k | 58.00% |
| EBITDA | -149.61k | 57.72% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.39m |
Number of shares | 32.51m |
52-week high/low | €0.61 - €0.41 |
| Dividends | No |
Beta | 0.58 |
P/E ratio | -14.31 |
PEG ratio | -0.30 |
P/B ratio | 1.81 |
P/S ratio | 2.66 |
Company profile
| Name | SENZAGEN AB |
| CEO | Peter Nahlstedt |
| Employees | 34 |
